IMMIX BIOPHARMA, INC. IMMX 深 沪
交易中 08-06 11:39:22 美东时间
2.741
-0.109
-3.82%
华盛通- 最 高2.95
- 今 开2.95
- 成交量 13.68万股
- 最 低 2.686
- 昨 收 2.85
- 总市值 7634.32万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 0.49%
- 52周最低 1.26
- 委 比 92.31%
- 总股本 2785.23万
- 历史最高 8.68
- 量 比 1.51
- 振 幅 9.26%
- 历史最低 0.68
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
<p>Immix Biopharma has reported a strong safety profile for its CAR-T therapy NXC-201, with no neurotoxicity observed in low-volume disease cases. The company is advancing toward submitting a Biologics License Application (BLA) for NXC-201 in relapsed/refractory AL Amyloidosis, a rare condition causing organ damage. NXC-201 has received FDA's Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation. The company aims to expand NXC...
07-11 13:36
Immix Biopharma Accelerates U.S. NEXICART-2 Clinical Trial In Relapsed/Refractory AL Amyloidosis; Says It Is On Track For First BLA Approved Cell Therapy In Unaddressed Orphan Indication
– National Footprint of NEXICART-2 Trial Sites Expanded –– On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication –– NEXICART-2 interim results were
07-07 21:37
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
Immix Biopharma expands NEXICART-2 clinical trial sites to 18 in the U.S., aiming to address unmet needs in relapsed/refractory AL Amyloidosis. NEXICART-2 interim results were presented at ASCO 2025. The company is on track for FDA BLA submission for its CAR-T therapy NXC-201, which has orphan drug designation and RMAT designation. AL Amyloidosis affects up to 33,277 patients in the U.S. with a growing prevalence of 12% annually.
07-07 13:35
Immix Biopharma Attends FDA CEO Forum in Washington DC
Immix Biopharma, Inc. was selected by the FDA to attend a CEO forum led by FDA Commissioner Marty A. Makary on June 5, 2025. The event aimed to gather input from industry leaders on modernizing the FDA's regulatory framework to support innovation and patient access to therapies. Immix's CEO and CFO expressed appreciation for the opportunity to discuss these matters and highlighted the company's lead CAR-T therapy, NXC-201, currently in a Phase 1/...
06-06 13:39
Immix Biopharma Enters At The Market Offering Agreement
The latest announcement is out from Immix Biopharma ( ($IMMX) ). On June 3, 202...
06-04 03:27
Immix Biopharma Reports NEXICART-2 Phase 1/2 Trial Results At 2025 ASCO, Meeting Primary Endpoint
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.– NXC-201 met primary endpoint with a complete response (CR) rate of
06-04 02:57
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma's NXC-201 met its primary endpoint in the Phase 1/2 NEXICART-2 trial for relapsed/refractory AL Amyloidosis, achieving a 70% complete response rate (7/10 patients) with no relapses or safety signals. The company plans a Biologics License Application (BLA) submission to the FDA. A Key Opinion Leader (KOL) event to discuss the results will be held on June 3, 2025.
06-03 18:55
Immix Biopharma Says 14 U.S. Sites Actively Enrolling In U.S. Multi-Site Study NEXICART-2; Anticipate Completing NEXICART-2 Clinical Trial Ahead Of Schedule
– Patient enrollment exceeding expectations –– 14 U.S. sites actively enrolling; 10 U.S. sites added since last update –– Anticipate completing NEXICART-2 clinical trial ahead of schedule –LOS ANGELES, CA, May 23, 2025
05-23 21:07
Market-Moving News for May 23rd
OKLO: 24% | Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday. BCAX: -36% | Bicara Therapeutics shares are
05-23 19:07
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
